Skip to main content
Clinical Trials/NCT05788120
NCT05788120
Recruiting
Not Applicable

Incidence and Morbidity of Cardiac Rhythm Disorders in Patients Assisted by Extra Corporeal Membrane Oxygenation Veno-arterial (ECMO VA) for Refractory Cardiogenic Shock

Assistance Publique - Hôpitaux de Paris35 sites in 1 country600 target enrollmentApril 28, 2023

Overview

Phase
Not Applicable
Intervention
Follow up by phone call
Conditions
Cardiac Rhythm Disorder
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment
600
Locations
35
Primary Endpoint
Number of atrial fibrillation in patients assisted by veno-arterial ECMO.
Status
Recruiting
Last Updated
15 days ago

Overview

Brief Summary

Brief Summary : Rhythm disorders are a frequent and potentially serious complication of critical patients in the ICU and postoperative cardiac surgery. In particular, atrial fibrillation (AF) is the most common rhythm disorder in patients admitted to the ICU and is associated with excess mortality during acute circulatory failure. In postoperative cardiac surgery, AF affects 15 to 45% of patients. In addition to hemodynamic effects, AF increases the risk of stroke, bleeding, respiratory or renal failure, and doubles mortality at 30 days and 6 months. In the longer term, the recurrence rate of AF within 1 year after hospital discharge is about 50%. Similarly, other rhythm disorders, supraventricular or ventricular, can be life-threatening in ICU patients.

While the incidence and complications of rhythm disorders are well documented during sepsis, cardiogenic shock or after cardiac surgery, there are to our knowledge no data on the frequency and complications of rhythm disorders in patients assisted by VA ECMO.

The primary objective is to describe the incidence of supraventricular rhythm disorders in patients assisted by VA ECMO.

Detailed Description

This study is an observational study to describe the conditions of occurrence of arrhythmias, particularly atrial fibrillation, in patients supported by VA ECMO, as well as their short-term and long-term prognosis. Patients will be recruited from the intensive care units and CRFs will be completed by the investigators at each of the participating centers. Data will be collected directly from the medical records, except for vital status at 1 year, which may be collected by telephone from the patient by the investigator at the center in the absence of data in the medical record. Atrial fibrillation episodes will be recorded on a 12-lead electrocardiogram and securely transmitted to the coordinating center. In addition, investigators will send weekly data to the principal investigator for incidence calculation. Patients or their relatives will be informed about the study by an information sheet presented and explained by the investigator or another person authorized to conduct the research. The investigator will record the patient's consent in the patient's medical record.

Registry
clinicaltrials.gov
Start Date
April 28, 2023
End Date
April 28, 2028
Last Updated
15 days ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient 18 years of age or older
  • Assistance with VA ECMO

Exclusion Criteria

  • Opposition to the use of data.
  • Persons under legal protection (curators, guardianship), judicially safeguarded.
  • VA ECMO for refractory cardiac arrest.

Arms & Interventions

Patients with refractory cardiogenic shock assisted with ECMO VA

Intervention: Follow up by phone call

Outcomes

Primary Outcomes

Number of atrial fibrillation in patients assisted by veno-arterial ECMO.

Time Frame: day 30

Atrial fibrillation will be defined as an episode of AF ≥ 30 minutes or requiring pharmacological or electrical cardioversion.

Secondary Outcomes

  • duration of ICU stay(day 30)
  • Number of ventricular rhythm disorders(day 30)
  • duration of VA ECMO support(day 30)
  • duration of mechanical ventilation(day 30)
  • Number of living patient(day 28, day 360)
  • Number of thrombo-embolic complications(day 30)
  • Number of neurological complications(day 30)
  • Number of bleeding complications(day 30)

Study Sites (35)

Loading locations...

Similar Trials